<DOC>
	<DOCNO>NCT01308684</DOCNO>
	<brief_summary>This open-label , multicenter study evaluate safety efficacy RO5323441 combination Avastin ( bevacizumab ) patient recurrent glioblastoma . In dose-finding part , patient receive intravenous escalate dos RO5323441 combination 10 mg/kg Avastin every two week . In efficacy-finding part , patient randomize receive establish dose ( dose-finding part ) RO5323441 plus Avastin Avastin alone . Patients dose-finding part may continue treatment RO5323441 Avastin study evidence progressive disease unacceptable adverse event happen . In efficacy-finding part , patient receive study treatment disease progression death .</brief_summary>
	<brief_title>A Dose- Efficacy-Finding Study RO5323441 Combination With Avastin ( Bevacizumab ) Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Histologically confirm glioblastoma Radiographic demonstration disease progression Response Assessment Neurooncology ( RANO ) criterion follow prior therapy Availability least 1 formalinfixed paraffinembedded tumor tissue sample If receiving corticosteroid , patient must stable decrease dose corticosteroid Prior standard radiotherapy glioblastoma Karnofsky Performance status &gt; /=70 Over 4 week since prior surgical resection Over 12 week radiotherapy Over 4 week anticancer agent Patients second later glioblastoma relapse Patients receive one systemic treatment regimen glioblastoma Patients secondary glioblastoma Prior treatment Avastin Patients unable undergo Magnetic Resonance Imaging ( MRI )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>